Drugs / stabilized chlorine dioxide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05258721 | Jul 2021 → Oct 2022 | gingivitis, periodontitis | Rowpar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04838054 | Mar 2018 → Jan 2020 | mucositis | Rowpar Pharmaceuticals, Inc. | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | stabilized chlorine dioxide | “ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v...” NCT05258721 ↗ |
| Route | Oral | “Stabilized chlorine dioxide oral rinse” NCT04838054 ↗ |